Resting Energy Expenditure Equations in Amyotrophic Lateral Sclerosis, Creation of a ALS-specific Equation
Introduction: Resting energy expenditure (REE) formulas for healthy people (HP) are used to calculate REE (cREE) in amyotrophic lateral sclerosis (ALS) patients. In ALS an increase of measured REE (mREE) in indirect calometry (IC) compared to cREE is found in 50-60%. The aims were (i) to assess accuracy of cREE assessed using eleven formulas as compared to mREE and (ii) to create if needed a specific cREE formula for ALS patients.
Method: ALS patients followed in the ALS expert center of Limoges between 1996 and 2014 and with a nutritional evaluation were included. mREE assessed with IC and cREE calculated with eleven predictive formulas (Harris Benedict (HB) 1919, HB 1984, WSchofield, De Lorenzo, Johnstone, Mifflin, WHO/FAO, Owen, Fleisch, Wang and Rosenbaum) were collected at time of diagnosis. Fat free mass (FFM) and fat mass (FM) were measured with impedancemetry. A Bland and Altman analysis was carried out. The percentage of accurate prediction ± 10%of mREE, and intraclass correlation coefficients (ICC) were calculated. Using a derivation sample, a new REE formula was created using multiple linear regression according to sex, age, FFM and FM. Accuracy of this formula was assessed in a validation sample.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Limoges, France, 87042
- CHU Limoges
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ALS diagnosed patients according to Airlie House criteria
- treated with riluzole
- respiratory quotient (RQ) of patients in indirect calorimetry (IC) should be in between 0.7 and 0.87
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Resting energy expenditure emeasures
Time Frame: nutritional assessement should have been be performed within a 1.5 months' time period. IC had to be performed no later than 12 months after diagnosis.
|
nutritional assessement should have been be performed within a 1.5 months' time period. IC had to be performed no later than 12 months after diagnosis.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ALS/jesus
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
NCT07618585Active, not recruitingALS (Amyotrophic Lateral Sclerosis) | ALS - Amyotrophic Lateral Sclerosis
-
NCT05928416Active, not recruitingAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, Sporadic
-
NCT07543367RecruitingALS (Amyotrophic Lateral Sclerosis) | Motor Neuron Disease | ALS | Neurological Disorder | ALS - Amyotrophic Lateral Sclerosis
-
NCT04394871RecruitingAmyotrophic Lateral Sclerosis Type 4 | Inherited Neurological Disorders of RNA Processing
-
NCT07400393Not yet recruitingALS (Amyotrophic Lateral Sclerosis) | ALS | ALS - Amyotrophic Lateral Sclerosis
-
NCT03449212SuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, Sporadic
-
NCT07143656Active, not recruitingAmyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis &Amp; Other Neuromuscular Disorders
-
NCT06249412RecruitingAmyotrophic Lateral Sclerosis ALS7
-
NCT07187388RecruitingAmyotrophic Lateral Sclerosis (ALS) | Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Primary Lateral Sclerosis (PLS)
-
NCT00330681CompletedAmyotrophic Lateral Sclerosis (ALS)
Clinical Trials on nutritional assessement
-
NCT03284840CompletedThyroid Diseases | Iron-deficiency | Vitamin D Deficiency | Nutritional Status | Vitamin B 12 Deficiency | Folic Acid Deficiency | Diet | Nutrient Deficiency | Micronutrient Deficiency
-
NCT06745817Enrolling by invitationPhysical Activity | Iron-deficiency | Vitamin D Deficiency | Nutritional Status | Body Composition | Vitamin B 12 Deficiency | Folic Acid Deficiency | Diet | Skin Elasticity | Nutrient Deficiency
-
NCT06622473Enrolling by invitation
-
NCT02874118CompletedFrail in HIV Population
-
NCT03609281CompletedCesarean Section; Dehiscence | Cesarean Wound; Dehiscence | Cesarean Scar Niche
-
NCT06147687RecruitingEndometriosis | Pelvic Pain | Infertility, Female
-
NCT04918199CompletedKidney Transplant Failure